Flt3 ligand Human Protein
CAT#: DA3543S
Flt3 ligand human protein, 2 µg
Size: 10 ug
Need it in bulk or customized? Get a free quote |
CNY 3,260.00
货期*
7周
规格
Product images
Specifications
Product Data | |
Species | Human |
Expression Host | E. coli |
Expression cDNA Clone or AA Sequence |
TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVASNLQD EELCGG LWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQPP P SCLRFVQTN ISRLLQETSE QLVALKPWIT RQNFSRCLEL QCQPDSS TLP PPWSPRPLEA TAPTA
|
Predicted MW | 17.6 kDa |
Purity | >98% by RP-HPLC, Anion-exchange FPLC, Silverstain |
Buffer | Presentation State: Purified State: Lyophilized (freeze-dried) without stabilizer |
Preparation | Lyophilized (freeze-dried) without stabilizer |
Protein Description | Flt3-ligand produced in E. coli is a soluble non-glycosylated 17.6 kDa polypeptide containing 155 amino acid residues which comprises the extracellular domain of the transmembrane flt3-ligand protein. |
Storage | Store lyophilized at 2-8°C for 6 months or at -20°C long term. After reconstitution store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing. |
Stability | Shelf life: one year from despatch. |
Bioactivity | Biological: Human rh Flt3-ligand is fully biologically active when compared to standards. The ED50 range is 0.5-1.0 ng/ml corresponding to a specific activity of 1-2MUnits/mg, calculated by the dose-dependant stimulation of the proliferation of Human OCMI-AML5 cells. |
Endotoxin | < 0.1 ng per µg (IEU/µg) of rh Flt3-Ligand |
Reference Data | |
RefSeq | NP_001191431 |
Locus ID | 2323 |
UniProt ID | P49771 |
Cytogenetics | 19q13.33 |
Synonyms | SL cytokine, FLT3LG, Flt3L |
Summary | Dendritic cells (DCs) provide the key link between innate and adaptive immunity by recognizing pathogens and priming pathogen-specific immune responses. FLT3LG controls the development of DCs and is particularly important for plasmacytoid DCs and CD8 (see MIM 186910)-positive classical DCs and their CD103 (ITGAE; MIM 604682)-positive tissue counterparts (summary by Sathaliyawala et al., 2010 [PubMed 20933441]).[supplied by OMIM, Jan 2011] |
Protein Families | Druggable Genome, ES Cell Differentiation/IPS, Secreted Protein, Transmembrane |
Protein Pathways | Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Pathways in cancer |
Documents
FAQs |
SDS |
Customer
Reviews
Loading...